Related Experiment Videos

Boophilus microplus anticoagulant protein: an antithrombin inhibitor isolated from the cattle tick saliva

F Horn1, P C dos Santos, C Termignoni

  • 1Centro de Biotecnologia, Departamento de Biofísica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil. fhorn@dna.cbiot.ufrgs.br

Insights

Scientists discovered a novel anticoagulant in cattle tick saliva that specifically inhibits thrombin, offering potential for new blood-thinning therapies.

Area of Science:

  • Biochemistry
  • Parasitology
  • Pharmacology

Background:

  • Saliva of the cattle tick *Boophilus microplus* contains bioactive compounds.
  • Tick saliva components play roles in host blood feeding and immune evasion.
  • Understanding these components can reveal novel therapeutic targets.

Purpose of the Study:

  • To isolate and characterize an anticoagulant from *Boophilus microplus* saliva.
  • To determine the inhibitory specificity and mechanism of the anticoagulant.
  • To evaluate its potential as a therapeutic agent.

Main Methods:

  • Crude saliva preparation and anticoagulant activity assays (recalcification time, prothrombin time).
  • Purification of the inhibitor using gel filtration, anion exchange, and affinity chromatography.
  • Molecular weight determination by SDS-PAGE and enzyme inhibition assays (chromogenic substrate assays).

Main Results:

  • Crude saliva exhibited anticoagulant properties, prolonging clotting times and inhibiting thrombin amidolytic activity.
  • A 60,000 Da inhibitor was purified with potent anticoagulant activity (IC50 100 nM–1.1 µM).
  • The inhibitor demonstrated specificity for thrombin, with no significant inhibition of Factor Xa or other tested serine proteases.

Conclusions:

  • A novel, thrombin-specific anticoagulant inhibitor was successfully isolated from *Boophilus microplus* saliva.
  • The inhibitor's mechanism is not tight-binding, suggesting a distinct interaction with thrombin.
  • This tick-derived anticoagulant represents a promising candidate for developing new antithrombotic drugs.

Related Concept Videos